A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects With Advanced Cancers
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs JNJ 64619178 (Primary)
- Indications B-cell lymphoma; Myelodysplastic syndromes; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 16 May 2019 Planned number of patients changed from 70 to 120.
- 23 Jul 2018 Status changed from not yet recruiting to recruiting.
- 04 Jul 2018 New trial record